Edgar Filing: NOVAVAX INC - Form 4

NOVAVAX	INC										
Form 4	000										
August 04, 2	_								OMB A	PPROVAL	
FORM	4 UNITE	D STATES			ND EXC , D.C. 205		IGE (COMMISSION		3235-0287	
if no long subject to Section 1 Form 4 o Form 5 obligation may cont	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940						January 31, 2005 Estimated average burden hours per response 0.5				
(Print or Type F	Responses)										
1. Name and Address of Reporting Person <u>*</u> Singhvi Rahul			2. Issuer Name and Ticker or Trading Symbol NOVAVAX INC [nvax]					5. Relationship of Reporting Person(s) to Issuer			
	(First) VAX, INC., 99 CAMPUS DF		3. Date of (Month/D 07/31/20	-	ransaction			_X_ Director _X_ Officer (give below)		e) 9 Owner er (specify	
	(Street)			ndment, Da th/Day/Yea	ate Original			6. Individual or Jo Applicable Line) _X_ Form filed by 0			
ROCKVILL	LE, MD 20850								More than One Re		
(City)	(State)	(Zip)	Table	e I - Non-I	Derivative S	ecurit	ies Acq	quired, Disposed of	f, or Beneficial	lly Owned	
1.Title of Security (Instr. 3)	2. Transaction I (Month/Day/Ye	ear) Executio any	med on Date, if Day/Year)	Code	on(A) or Di (D) (Instr. 3, 4	sposed	of	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		
Common Stock	07/31/2008			Р	10,554		<u>(1)</u>	221,438 <u>(2)</u>	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: NOVAVAX INC - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. Number onof Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8 I S (
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Warrant - right to buy	\$ 3.62	07/31/2008		Р	5,277	01/31/2009	07/31/2013	Common Stock	5,277	

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
Singhvi Rahul C/O NOVAVAX, INC. 9920 BELWARD CAMPUS DRIVE ROCKVILLE, MD 20850	Х		President, CEO				
Signatures							
/s/ Len Stigliano, as attorney-in-fact fo	or Rahul		08/04/2008				

**Signature of Reporting Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The reported securities are included within 10,554 Units purchased by the Reporting Person for \$2.845 per Unit. Each Unit consists of one share of Common Stock and a warrant to purchase .5 shares of Common Stock.

Date

(2) Includes 58,334 shares of Restricted Common Stock that have not yet vested.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Singhvi

8 D S (]